Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc.verified

JNCE

Price:

$1.88

Market Cap:

$98.95M

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics...[Read more]

Industry

Biotechnology

IPO Date

2017-01-26

Stock Exchange

NASDAQ

Ticker

JNCE

The PE Ratio as of April 2024 (TTM) for Jounce Therapeutics, Inc. (JNCE) is -1.96

According to Jounce Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.96. This represents a change of 86.15% compared to the average of -1.05 of the last 4 quarters.

Jounce Therapeutics, Inc. (JNCE) Historical PE Ratio (quarterly & annually)

How has JNCE PE Ratio performed in the past?

The mean historical PE Ratio of Jounce Therapeutics, Inc. over the last ten years is -13.20. The current -1.96 PE Ratio has changed 1.38% with respect to the historical average. Over the past ten years (40 quarters), JNCE's PE Ratio was at its highest in in the December 2021 quarter at 3.57K. The PE Ratio was at its lowest in in the June 2017 quarter at -33.36.

Quarterly (TTM)
Annual

Average

-13.20

Median

-5.66

Minimum

-37.97

Maximum

5.27

Jounce Therapeutics, Inc. (JNCE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Jounce Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 239.07%

Maximum Annual PE Ratio = 5.27

Minimum Annual Increase = -231.44%

Minimum Annual PE Ratio = -37.97

Quarterly (TTM)
Annual
YearPE RatioChange
2022-1.13-75.45%
2021-4.59-18.89%
2020-5.66-207.35%
20195.27-231.44%
2018-4.01-82.80%
2017-23.30-38.62%
2016-37.97239.07%
2015-11.20-69.10%

Jounce Therapeutics, Inc. (JNCE) Average PE Ratio

How has JNCE PE Ratio performed in the past?

The current PE Ratio of Jounce Therapeutics, Inc. (JNCE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.79

5-year avg

-2.02

10-year avg

-13.20

Jounce Therapeutics, Inc. (JNCE) PE Ratio vs. Peers

How is JNCE’s PE Ratio compared to its peers?

Jounce Therapeutics, Inc.’s PE Ratio is less than Assembly Biosciences, Inc. (-1.20), less than Spero Therapeutics, Inc. (3.13), less than Achilles Therapeutics plc (-0.45), less than Instil Bio, Inc. (-0.45), less than Neoleukin Therapeutics, Inc. (-0.98), less than CytomX Therapeutics, Inc. (63.40), less than NextCure, Inc. (-0.73), greater than Nuvation Bio Inc. (-8.27),

Build a custom stock screener for Jounce Therapeutics, Inc. (JNCE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Jounce Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Jounce Therapeutics, Inc. (JNCE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Jounce Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Jounce Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Jounce Therapeutics, Inc. (JNCE)?

What is the highest PE Ratio for Jounce Therapeutics, Inc. (JNCE)?

What is the 3-year average PE Ratio for Jounce Therapeutics, Inc. (JNCE)?

What is the 5-year average PE Ratio for Jounce Therapeutics, Inc. (JNCE)?

How does the current PE Ratio for Jounce Therapeutics, Inc. (JNCE) compare to its historical average?